> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BioNTech Agrees to Buy Priority Voucher for $205 Million
- URL: https://www.fdaweb.com/biontech-agrees-to-buy-priority-voucher-for-205-million/
- Published: 2026-11-11T18:29:44.000Z
- Updated: 2026-11-11T18:29:44.000Z
- Author: David McFarland
- Tags: Drugs

BioNTech says it has entered into an agreement to acquire for $205 million an FDA Priority Review Voucher that was awarded to Scholar Rock. The voucher grants an FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval.

BioNTech says it intends to use the voucher to “support a future filing of an asset in its late-stage oncology pipeline.” The company did not identify the oncology candidate for which it intends to use the voucher. One possibility is pumitamig (BNT327), a PD-L1/VEGF-A bispecific antibody being developed with Bristol Myers Squibb. The drug's substantial commercial potential could make an accelerated FDA review particularly valuable. Another possibility is trastuzumab pamirtecan (BNT323), for which BioNTech and DualityBio have been discussing a potential BLA submission.